Lexaria Bioscience Corp
LEXX
查看详细走势图
0.583USD
-0.103-14.96%
收盘 12/19, 16:00（美东）报价延迟15分钟
11.40M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-14.96%
5天
-56.52%
1月
-47.28%
6月
-39.31%
今年开始到现在
-72.26%
1年
-73.87%
查看详细走势图
TradingKey Lexaria Bioscience Corp股票评分
单位: USD 更新时间: 2025-12-19操作建议
Lexaria Bioscience Corp当前公司基本面数据相对健康，增长潜力很大。当前估值合理，在药品行业排名101/158位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价5.33。中期看，股价处于下降通道。近一个月，市场表现非常差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Lexaria Bioscience Corp评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
2
位分析师
买入
评级
5.333
目标均价
+389.30%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Lexaria Bioscience Corp亮点
亮点风险
Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company's patented drug delivery formulation and processing platform technology improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has also evidenced an ability to deliver some drugs effectively across the blood brain barrier. The Company’s segment includes Intellectual Property, B2B Production, and Research and Development. It is advancing several research and development (R&D) activities in both preclinical and clinical programs. Its focus is the investigation and the incorporation of its DehydraTECH drug delivery technology with glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) to enhance absorption and reduce adverse side effects. The Company operates a licensed in-house research laboratory and holds an intellectual property portfolio with around 48 patents granted and many patents pending worldwide.
业绩高增长
公司营业收入稳步增长，连续3年增长212.07%
业绩增长期
公司处于发展阶段，最新年度总收入705.92K美元
利润高增长
公司净利润处于行业前列，最新年度总收入705.92K美元
估值高估
公司最新PE估值-0.88，处于3年历史高位
机构加仓
最新机构持股2.42M股，环比增加7.37%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值258.82K
Lexaria Bioscience Corp新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Lexaria Bioscience Corp简介
Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company's patented drug delivery formulation and processing platform technology improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has also evidenced an ability to deliver some drugs effectively across the blood brain barrier. The Company’s segment includes Intellectual Property, B2B Production, and Research and Development. It is advancing several research and development (R&D) activities in both preclinical and clinical programs. Its focus is the investigation and the incorporation of its DehydraTECH drug delivery technology with glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) to enhance absorption and reduce adverse side effects. The Company operates a licensed in-house research laboratory and holds an intellectual property portfolio with around 48 patents granted and many patents pending worldwide.
公司代码LEXX
公司Lexaria Bioscience Corp
CEOChristopher (Richard)
网址https://www.lexariabioscience.com/
常见问题
Lexaria Bioscience Corp(LEXX)的当前股价是多少？
Lexaria Bioscience Corp(LEXX)的当前股价是 0.583。
Lexaria Bioscience Corp的股票代码是什么？
Lexaria Bioscience Corp的股票代码是LEXX。
Lexaria Bioscience Corp股票的52周最高点是多少？
Lexaria Bioscience Corp股票的52周最高点是2.430。
Lexaria Bioscience Corp股票的52周最低点是多少？
Lexaria Bioscience Corp股票的52周最低点是0.660。
Lexaria Bioscience Corp的市值是多少？
Lexaria Bioscience Corp的市值是11.40M。
Lexaria Bioscience Corp的净利润是多少？
Lexaria Bioscience Corp的净利润为-11.90M。
现在Lexaria Bioscience Corp(LEXX)的股票是买入、持有还是卖出？
根据分析师评级，Lexaria Bioscience Corp(LEXX)的总体评级为买入，目标价格为5.333。
Lexaria Bioscience Corp(LEXX)股票的每股收益（EPS TTM）是多少
Lexaria Bioscience Corp(LEXX)股票的每股收益（EPS TTM）是-0.661。
相关品种
